Biocon Biologics Limited (BBL), a global biosimilars company, partners with Eris Lifesciences to expand patient access to Metabolics, Oncology, and Critical Care products in India. This extends their existing collaboration for Nephrology and Dermatology products. The deal, valued at INR 12,420 million, includes a 10-year supply agreement and ensures continuity for 430 transitioning employees. Effective April 1, 2024, subject to customary closing conditions, this strategic move aligns with Biocon Biologics' goal to maximize market potential and patient reach. CEO Shreehas Tambe highlights the commitment to delivering high-quality biosimilars to millions of Indian patients. With a legacy of impacting lives through diabetes, cancer, and critical care products, Biocon Biologics remains dedicated to providing affordable healthcare solutions. This partnership underscores their mission to bridge healthcare gaps and make a significant difference in patient outcomes globally.

CEO Shreehas Tambe highlights the commitment to delivering high-quality biosimilars to millions of Indian patients.